4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report released on Monday,Benzinga reports. They currently have a $36.00 price objective on the stock.

A number of other equities analysts have also issued reports on the stock. Chardan Capital reaffirmed a “buy” rating and set a $39.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Leerink Partners dropped their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $40.00 to $15.00 in a research note on Monday, January 13th. Morgan Stanley lowered their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research note on Monday, January 13th. Finally, Bank of America reduced their price objective on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.13.

4D Molecular Therapeutics Stock Down 0.7 %

Shares of NASDAQ FDMT opened at $4.55 on Monday. 4D Molecular Therapeutics has a 12 month low of $4.41 and a 12 month high of $36.25. The company has a market cap of $210.34 million, a P/E ratio of -1.60 and a beta of 2.81. The business’s 50 day moving average is $5.69 and its two-hundred day moving average is $9.53.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. lifted its holdings in shares of 4D Molecular Therapeutics by 238.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock valued at $16,684,000 after acquiring an additional 1,087,147 shares during the period. Braidwell LP increased its position in shares of 4D Molecular Therapeutics by 231.7% during the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after purchasing an additional 855,990 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in 4D Molecular Therapeutics by 159.5% during the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company’s stock valued at $4,568,000 after purchasing an additional 504,086 shares during the last quarter. Norges Bank acquired a new position in 4D Molecular Therapeutics in the fourth quarter valued at about $2,790,000. Finally, Redmile Group LLC grew its stake in 4D Molecular Therapeutics by 17.6% during the third quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock worth $13,643,000 after buying an additional 188,655 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.